J A Slack

NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA

B.J. Denny, Richard T. Wheelhouse, Malcolm F. G. Stevens et al. · Biochemistry · 1994 · 437 citations

Drug Target, Bioorganic Chemistry, Molecular Biology +19

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

M. F. G. STEVENS, J A Hickman, S P Langdon et al. · PubMed · 1987 · 390 citations

Antitumor Activity, Pharmacotherapy, Metronomic Chemotherapy +17

Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

Lincoln L. H. Tsang, Charmaine P. Quarterman, Andreas Gescher et al. · Cancer Chemotherapy and Pharmacology · 1991 · 92 citations

Medicinal Chemistry, Pharmaceutical Science, Pharmacological Study +8

Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity

Lincoln L. H. Tsang, Peter B. Farmer, Andreas Gescher et al. · Cancer Chemotherapy and Pharmacology · 1990 · 65 citations

Medicinal Chemistry, Urinary Metabolites, Comparative Toxicology +11

Phase I clinical trial of mitozolomide.

ES Newlands, G. Blackledge, J A Slack et al. · PubMed · 1985 · 51 citations

Broad Spectrum Activity, Pathology, Pharmacotherapy +16